These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1061 related articles for article (PubMed ID: 2942646)

  • 21. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
    Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
    Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
    Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
    Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
    Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I studies of recombinant interferon-gamma.
    Laszlo J; Goldstein D; Gockerman J; Hood L; Huang AT; Triozzi P; Sedwick WD; Koren H; Ellinwood EH; Tso CY
    J Biol Response Mod; 1990 Apr; 9(2):185-93. PubMed ID: 2160521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I clinical trial of carbetimer.
    Hanauske AR; Melink TJ; Harman GS; Clark GM; Craig JB; Koeller JM; Boldt DH; Kantor B; Kisner DL; Orczyk G
    Cancer Res; 1988 Sep; 48(18):5353-7. PubMed ID: 2842047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-alpha in patients with malignant melanoma.
    Caulfield MJ; Barna B; Murthy S; Tubbs R; Sergi J; Medendorp S; Bukowski RM
    J Biol Response Mod; 1990 Jun; 9(3):319-28. PubMed ID: 2380747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
    Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
    Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of weekly high-dose human lymphoblastoid interferon.
    Connors JM; Silver HK
    Cancer Treat Rep; 1984 Sep; 68(9):1093-6. PubMed ID: 6478449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
    Karavodin LM; Golub SH
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II clinical evaluation of doxifluridine.
    Hurteloup P; Armand JP; Cappelaere P; Metz R; Kerbrat P; Keiling R; Fumoleau P; Fargeot P; Schraub S; Bastit P
    Cancer Treat Rep; 1986 Jun; 70(6):731-7. PubMed ID: 2942245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
    Berd D; Mastrangelo MJ
    Cancer Res; 1988 Mar; 48(6):1671-5. PubMed ID: 2830969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial clinical trials with 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NCS-112682).
    Luce JK; Bodey GP
    Cancer Chemother Rep; 1970 Apr; 54(2):131-4. PubMed ID: 4946003
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
    Eskens FA; Greim GA; van Zuylen C; Wolff I; Denis LJ; Planting AS; Muskiet FA; Wanders J; Barbet NC; Choi L; Capdeville R; Verweij J; Hanauske AR; Bruntsch U
    Clin Cancer Res; 2000 May; 6(5):1736-43. PubMed ID: 10815892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of the lymphocyte blast transformation reaction for evaluating cellular immunity function].
    Korneeva MN; Novokhatskiĭ AS; Grebeniuk VN; Kerimov SG
    Biull Eksp Biol Med; 1989 Apr; 107(4):469-71. PubMed ID: 2524230
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
    J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activation of specific helper and suppressor T cells by the type 2 antigen polyvinylpyrrolidone (PVP).
    Van Buskirk AM; Braley-Mullen H
    J Immunol; 1987 Sep; 139(5):1400-5. PubMed ID: 2957424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.